Cleveland BioLabs, Inc.
http://www.cbiolabs.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cleveland BioLabs, Inc.
Asia Deal Watch: Aditum Bio Launches Vitalli To Develop Daewoong Immunology Candidate
In addition, deals involving Lupin/Medisol, Junshi/Dr. Reddy's, Zai Lab/MediLink, Kyowa Kirin/ADVANZ, Ipca/Unichem, Jiangsu Aidea/Kainos.
Korea Q1 Roundup: Mixed Earnings Amid M&A, Prescription Sales
Large Korean pharma firms’ first-quarter earnings were mostly mixed on a range of diverse factors such as solid prescription sales and impacts from acquisitions, with some even looking to space for new business opportunities.
In Vivo’s 2023 Rising Leaders: Healthcare Innovators At The Top Of Their Game
The fourth annual listing of In Vivo’s ‘Rising Leaders’ includes entrepreneurs and innovators from across the world who represent the next wave of creativity in healthcare.
Kinnate Zeroes In On BRAF Subpopulation For Exarafenib Development Strategy
Kinnate presented early monotherapy and combination data for its pan-RAF inhibitor at AACR, but its prioritization of BRAF Class II drew analyst concerns that its focus might be too narrow.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- BioLab 612, LLC, Incuron, LLC
- Panacela Labs, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice